Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K; CONFIRM Study Investigators.
N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290.
Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.
Velez JCQ.
Kidney360. 2021 Dec 3;3(2):382-395. doi: 10.34067/KID.0006722021. eCollection 2022 Feb 24.
Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.
Facciorusso A.
Ther Clin Risk Manag. 2019 Nov 27;15:1383-1391. doi: 10.2147/TCRM.S205328. eCollection 2019.
Hepatorenal Syndrome Type 1: Diagnosis and Treatment.
Belcher JM.
Adv Kidney Dis Health. 2024 Mar;31(2):100-110. doi: 10.1053/j.akdh.2023.05.001.
Hepatorenal syndrome: Current concepts and future perspectives.
Jung CY, Chang JW.
Clin Mol Hepatol. 2023 Oct;29(4):891-908. doi: 10.3350/cmh.2023.0024. Epub 2023 Apr 13.
Pathophysiology of Hepatorenal Syndrome.
Velez JCQ, Latt N, Rodby RA.
Adv Kidney Dis Health. 2024 Mar;31(2):87-99. doi: 10.1053/j.akdh.2024.01.002.
Terlipressin for Type 1 Hepatorenal Syndrome.
Terbah R, Gow P, Sinclair M, Testro A.
Dig Dis Sci. 2020 Aug;65(8):2454-2455. doi: 10.1007/s10620-020-06370-8. Epub 2020 Jun 8.
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.
Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR.
J Hepatol. 2019 Oct;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11.
Hepatorenal syndrome.
Angeli P, Morando F, Cavallin M, Piano S.
Contrib Nephrol. 2011;174:46-55. doi: 10.1159/000329235. Epub 2011 Sep 9.
Hypoalbuminemia.
Gatta A, Verardo A, Bolognesi M.
Intern Emerg Med. 2012 Oct;7 Suppl 3:S193-9. doi: 10.1007/s11739-012-0802-0.
